DT2216 has demonstrated preclinical activity against BCL-XL -dependent T cell lymphomas without causing significant platelet toxicity specifically degrading BCL-XL while sparing BCL-2 [47,49]. This evidence concerns the gene BCL2L1 and T-cell non-Hodgkin lymphoma.